Last reviewed · How we verify
Standard dose oxcarbazepine
Oxcarbazepine blocks voltage-gated sodium channels in neuronal membranes, reducing repetitive neuronal firing and stabilizing hyperexcited neural tissue.
Oxcarbazepine blocks voltage-gated sodium channels in neuronal membranes, reducing repetitive neuronal firing and stabilizing hyperexcited neural tissue. Used for Partial-onset seizures (monotherapy and adjunctive therapy), Generalized tonic-clonic seizures (adjunctive therapy), Bipolar disorder (off-label use).
At a glance
| Generic name | Standard dose oxcarbazepine |
|---|---|
| Also known as | Standard oxcarbazepine |
| Sponsor | Mario Negri Institute for Pharmacological Research |
| Drug class | Anticonvulsant; sodium channel blocker |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Oxcarbazepine is a prodrug that is rapidly metabolized to its active metabolite, 10-monohydroxy derivative (MHD). This metabolite binds to inactivated sodium channels, preventing their reopening and thereby reducing the propagation of action potentials. Additionally, it may enhance potassium conductance and modulate calcium channels, contributing to its anticonvulsant and mood-stabilizing effects.
Approved indications
- Partial-onset seizures (monotherapy and adjunctive therapy)
- Generalized tonic-clonic seizures (adjunctive therapy)
- Bipolar disorder (off-label use)
Common side effects
- Dizziness
- Somnolence
- Diplopia
- Ataxia
- Nausea
- Hyponatremia
- Rash (including Stevens-Johnson syndrome)
Key clinical trials
- Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW) (PHASE4)
- Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain (PHASE1)
- Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: